Health Care Services

23andMe

Financial Analysis

MercadoLibre

MELI

09988

BABA

89988

KBAB

BABO

BABX

COST

MEHCQ

VCTR

HBBD

<p>The Latin American version of &#34;Alibaba&#34;—<span class="security-tag" type="security-tag" counter_id="ST/US/MELI" name="Mercadolibre" trend="">$Mercadolibre(MELI.US)</span> (hereinafter referred to as Meli) released its financial report for the third quarter of 2025 on October 30. Overall, the revenue side performed well, with accelerated growth quarter-on-quarter and slightly exceeding expectations. Conversely, due to increased logistics subsidies within the e-commerce segment and a decline in financial business due to structural factors and interest rates, profit margins fell short of sell-side expectations. 1. Growth outperformed but profits underperformed: In terms of overall performance, Meli's total revenue (denominated in USD) grew approximately 39.5% year-on-year, with a significant acceleration from the previous quarter...</p>

Mercadolibre

BABA-W

Alibaba

BABA-WR

KraneShares 2x Long BABA Daily ETF

YieldMax BABA Option Income Strategy ETF

BABA 2x Long Daily ETF - GraniteShares

Costain Group PLC

Costco Wholesale

MoneyLion

CHROME HLDG CO

Pro Ultra 7-10Yrs

Victory

Alibaba HK SDR 5to1

Meli: Profit miss? It might just be the 'growing pains' before victory.

23andMe Sees 37% Year-Over-Year Revenue Decline in Q1

Anne Wojcicki wins 23andMe bid for $305 million

23andMe Seeks Bids for Customer Genetic Data

U.S. Corporate Bankruptcies Reach 188 Cases in Q1, a 15-Year High

Sei Foundation Plans to Acquire Bankrupt Genetic Testing Company 23andMe

23andMe Initiates Voluntary Chapter 11 Bankruptcy to Facilitate Asset Sale

23andMe Launches New Homocysteine Genetic Report and Blood Testing Service

23andMe's stock drops 31.4%, CEO proposes to acquire remaining shares at $0.41 each

Anne Wojcicki Proposes Privatization of 23andMe Holdings Co.

23andMe released FY2025 Q3 earnings on January 28 (EST), actual revenue 60.26 M USD (forecast 65 M USD), actual EPS -2.0127 USD (forecast -3.1862 USD)

23andMe released FY2025 9 Months Earnings on January 28 (EST), with actual revenue of 144.75 M USD and EPS of -7.1277 USD

23andMe Reports Q3 FY2025 Financial Performance, Significant Liquidity and Operational Challenges

23andMe released FY2025 Q2 earnings on November 12 After-Market (EST), actual revenue $44.071M (forecast $54.3M), actual EPS -2.3159 (forecast -3.1524)

23andMe released FY2025 Semi-Annual Earnings on November 12 After-Market (EST), with actual revenue of 84,485,000 USD and EPS of -5.109

23andMe to Release FY2025 Q2 Earnings on November 12 After-Market EST, Forecast Revenue 54.3 M USD, EPS -3.1524 USD

Anne Wojcicki Decides Not to Consider Third-Party Acquisition Proposals

Bleichmar Fonti & Auld LLP Investigates 23andMe CEO Anne Wojcicki's Fiduciary Duties

Bleichmar Fonti & Auld LLP Investigates 23andMe

Bleichmar Fonti & Auld LLP Investigates 23andMe Holdings

23andMe Renames to 'Me', Focusing on Personal Genetic Data

PicoCELA

Santech

Highway

Trinity Biotech

Euda Health

Aimei Health Tech

Sable Offshore

Pomdoctor

Ascent Solar Tech

A SPAC III Acquisition

Cigna

BrightSpring Health Services - Unit

Labcorp

Quest Diagnostics

Hims & Hers Health

BrightSpring Health Services

Chemed

Option Care Health

GeneDx

CorVel

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap